<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34497368</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4679</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature cell biology</Title>
          <ISOAbbreviation>Nat Cell Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination.</ArticleTitle>
        <Pagination>
          <StartPage>978</StartPage>
          <EndPage>991</EndPage>
          <MedlinePgn>978-991</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41556-021-00732-8</ELocationID>
        <Abstract>
          <AbstractText>The extracellular-signal-regulated kinases ERK1 and ERK2 (hereafter ERK1/2) represent the foremost mitogenic pathway in mammalian cells, and their dysregulation drives tumorigenesis and confers therapeutic resistance. ERK1/2 are known to be activated by MAPK/ERK kinase (MEK)-mediated phosphorylation. Here, we show that ERK1/2 are also modified by lysine-63 (K63)-linked polyubiquitin chains. We identify the tripartite motif-containing protein TRIM15 as a ubiquitin ligase and the tumour suppressor CYLD as a deubiquitinase of ERK1/2. TRIM15 and CYLD regulate ERK ubiquitination at defined lysine residues through mutually exclusive interactions as well as opposing activities. K63-linked polyubiquitination enhances ERK interaction with and activation by MEK. Downregulation of TRIM15 inhibits the growth of both drug-responsive and drug-resistant melanomas. Moreover, high TRIM15 expression and low CYLD expression are associated with poor prognosis of patients with melanoma. These findings define a role of K63-linked polyubiquitination in the ERK signalling pathway and suggest a potential target for cancer therapy.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Guixin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herlyn</LastName>
            <ForeName>Meenhard</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0839-0739</Identifier>
            <AffiliationInfo>
              <Affiliation>Molecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xiaolu</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-6755-7725</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. xyang@pennmedicine.upenn.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. xyang@pennmedicine.upenn.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA243520</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA010815</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA184867</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA182675</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA235760</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 AR069589</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Cell Biol</MedlineTA>
        <NlmUniqueID>100890575</NlmUniqueID>
        <ISSNLinking>1465-7392</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000597019">tripartite motif-containing protein 15, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>120904-94-1</RegistryNumber>
          <NameOfSubstance UI="D025821">Polyubiquitin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="C409984">CYLD protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.19.12</RegistryNumber>
          <NameOfSubstance UI="D000074749">Deubiquitinating Enzyme CYLD</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K3Z4F929H6</RegistryNumber>
          <NameOfSubstance UI="D008239">Lysine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074749" MajorTopicYN="N">Deubiquitinating Enzyme CYLD</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016147" MajorTopicYN="N">Genes, Tumor Suppressor</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025821" MajorTopicYN="N">Polyubiquitin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34497368</ArticleId>
        <ArticleId IdType="mid">NIHMS1722171</ArticleId>
        <ArticleId IdType="pmc">PMC8440396</ArticleId>
        <ArticleId IdType="doi">10.1038/s41556-021-00732-8</ArticleId>
        <ArticleId IdType="pii">10.1038/s41556-021-00732-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Morrison DK MAP kinase pathways. Cold Spring Harb Perspect Biol 4 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3536342</ArticleId>
            <ArticleId IdType="pubmed">23125017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaul YD &amp; Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta
1773, 1213–1226 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17112607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavoie H, Gagnon J. &amp; Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol
21, 607–632 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32576977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelstein B. et al.Cancer genome landscapes. Science 339, 1546–1558 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3749880</ArticleId>
            <ArticleId IdType="pubmed">23539594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen CM et al.COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3058384</ArticleId>
            <ArticleId IdType="pubmed">21107320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazarian R. et al.Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3143360</ArticleId>
            <ArticleId IdType="pubmed">21107323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva J. et al.Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026446</ArticleId>
            <ArticleId IdType="pubmed">21156289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samatar AA &amp; Poulikakos PI
Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov
13, 928–942 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25435214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryan MB, Der CJ, Wang-Gillam A. &amp; Cox AD
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer
1, 183–198 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4743050</ArticleId>
            <ArticleId IdType="pubmed">26858988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komander D. &amp; Rape M. The ubiquitin code. Annu Rev Biochem
81, 203–229 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22524316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng L. et al.Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351–361 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11057907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C. et al.TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346–351 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11460167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WL et al.The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134–1138 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3008763</ArticleId>
            <ArticleId IdType="pubmed">19713527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan CH et al.The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149, 1098–1111 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3586339</ArticleId>
            <ArticleId IdType="pubmed">22632973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ZJ &amp; Sun LJ
Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell
33, 275–286 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19217402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulathu Y. &amp; Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol
13, 508–523 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22820888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yau R. &amp; Rape M. The increasing complexity of the ubiquitin code. Nat Cell Biol
18, 579–586 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27230526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozato K, Shin DM, Chang TH &amp; Morse HC 3rd
TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol
8, 849–860 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433745</ArticleId>
            <ArticleId IdType="pubmed">18836477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 11, 792–804 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21979307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo L. et al.A cellular system that degrades misfolded proteins and protects against neurodegeneration. Mol Cell 55, 15–30 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4445634</ArticleId>
            <ArticleId IdType="pubmed">24882209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Zhu G, Johns EM &amp; Yang X. TRIM11 activates the proteasome and promotes overall protein degradation by regulating USP14. Nat Commun
9, 1223 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5964324</ArticleId>
            <ArticleId IdType="pubmed">29581427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L. et al.Enhanced degradation of misfolded proteins promotes tumorigenesis. Cell Rep 18, 3143–3154 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5603913</ArticleId>
            <ArticleId IdType="pubmed">28355566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y. et al.TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun 11, 348 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6969153</ArticleId>
            <ArticleId IdType="pubmed">31953436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu G. et al.TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson’s Disease. Cell Rep 33, 108418 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7906527</ArticleId>
            <ArticleId IdType="pubmed">33264628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pertel T. et al.TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361–365 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081621</ArticleId>
            <ArticleId IdType="pubmed">21512573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q. et al.Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc Natl Acad Sci U S A 108, 19341–19346 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3228454</ArticleId>
            <ArticleId IdType="pubmed">22084099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McEwan WA et al.Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14, 327–336 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672961</ArticleId>
            <ArticleId IdType="pubmed">23455675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gack MU et al.TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916–920 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17392790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Bergami P. et al.Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447–460 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1978100</ArticleId>
            <ArticleId IdType="pubmed">17482134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGill GG et al.Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707–718 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12086670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YJ, Tsang T, Anderson GR, Posimo JM &amp; Brady DC
Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF(V600E)-Driven Melanoma. Cancer Res
80, 1387–1400 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7127963</ArticleId>
            <ArticleId IdType="pubmed">32005716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman PB et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507–2516 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3549296</ArticleId>
            <ArticleId IdType="pubmed">21639808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz EM, Ghandi M, Treacy DJ, Wagle N. &amp; Garraway LA
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer research
74, 7079–7089 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4300142</ArticleId>
            <ArticleId IdType="pubmed">25320010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bardwell L. &amp; Thorner J. A conserved motif at the amino termini of MEKs might mediate high-affinity interaction with the cognate MAPKs. Trends Biochem Sci
21, 373–374 (1996).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8918190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanoue T. &amp; Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal
15, 455–462 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12639708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanoue T, Adachi M, Moriguchi T. &amp; Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol
2, 110–116 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10655591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinoshita T. et al.Crystal structure of human mono-phosphorylated ERK1 at Tyr204. Biochem Biophys Res Commun 377, 1123–1127 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18983981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor SS &amp; Kornev AP
Protein kinases: evolution of dynamic regulatory proteins. Trends in biochemical sciences
36, 65–77 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084033</ArticleId>
            <ArticleId IdType="pubmed">20971646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66, 105–143 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22569528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi DR et al.Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 13, 1610–1619 (1994).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC394991</ArticleId>
            <ArticleId IdType="pubmed">8157000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mevissen TET &amp; Komander D. Mechanisms of Deubiquitinase Specificity and Regulation. Annu Rev Biochem
86, 159–192 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28498721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clague MJ, Urbe S. &amp; Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol
20, 338–352 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30733604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Z, Xu S, Joazeiro C, Cobb MH &amp; Hunter T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell
9, 945–956 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12049732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y. et al.Nitration-induced ubiquitination and degradation control quality of ERK1. Biochem J 476, 1911–1926 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6604951</ArticleId>
            <ArticleId IdType="pubmed">31196894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bignell GR et al.Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25, 160–165 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10835629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun SC CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17, 25–34 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5848464</ArticleId>
            <ArticleId IdType="pubmed">19373246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massoumi R. et al.Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206, 221–232 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2626666</ArticleId>
            <ArticleId IdType="pubmed">19124656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trompouki E. et al.CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793–796 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12917689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brummelkamp TR, Nijman SM, Dirac AM &amp; Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature
424, 797–801 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12917690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovalenko A. et al.The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801–805 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12917691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin-Salomon V, Kogan K, Ahn NG, Livnah O. &amp; Engelberg D. Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinases. J Biol Chem
283, 34500–34510 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3259889</ArticleId>
            <ArticleId IdType="pubmed">18829462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies H. et al.Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12068308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flaherty KT et al.Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363, 809–819 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724529</ArticleId>
            <ArticleId IdType="pubmed">20818844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollag G. et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948082</ArticleId>
            <ArticleId IdType="pubmed">20823850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Planchard D. et al.Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17, 984–993 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4993103</ArticleId>
            <ArticleId IdType="pubmed">27283860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long GV et al.Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 5, 5694 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25452114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizos H. et al.BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 20, 1965–1977 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24463458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krepler C. et al.A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21, 1953–1967 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5726788</ArticleId>
            <ArticleId IdType="pubmed">29141225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L. et al.Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Molecular cancer research : MCR 6, 760–769 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756991</ArticleId>
            <ArticleId IdType="pubmed">18505921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talantov D. et al.Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 7234–7242 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16243793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchil PD et al.TRIM15 is a focal adhesion protein that regulates focal adhesion disassembly. J Cell Sci 127, 3928–3942 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4163643</ArticleId>
            <ArticleId IdType="pubmed">25015296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang WL et al.Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal 6, ra3 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3862898</ArticleId>
            <ArticleId IdType="pubmed">23300340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang J. et al.Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8, 855–862 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16845383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang P. et al.p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13, 310–316 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3110666</ArticleId>
            <ArticleId IdType="pubmed">21336310</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
